ATE271607T1 - Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3) - Google Patents

Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)

Info

Publication number
ATE271607T1
ATE271607T1 AT96940658T AT96940658T ATE271607T1 AT E271607 T1 ATE271607 T1 AT E271607T1 AT 96940658 T AT96940658 T AT 96940658T AT 96940658 T AT96940658 T AT 96940658T AT E271607 T1 ATE271607 T1 AT E271607T1
Authority
AT
Austria
Prior art keywords
grave
transplants
lag
recovery
preventing
Prior art date
Application number
AT96940658T
Other languages
English (en)
Inventor
Mauro Biffoni
Ruben Papoian
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE271607T1 publication Critical patent/ATE271607T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96940658T 1996-11-29 1996-11-29 Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3) ATE271607T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1996/005280 WO1998023748A1 (en) 1996-11-29 1996-11-29 Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)

Publications (1)

Publication Number Publication Date
ATE271607T1 true ATE271607T1 (de) 2004-08-15

Family

ID=8166413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96940658T ATE271607T1 (de) 1996-11-29 1996-11-29 Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)

Country Status (19)

Country Link
US (1) US6500422B2 (de)
EP (1) EP0941329B1 (de)
JP (1) JP3920928B2 (de)
KR (1) KR100481230B1 (de)
AR (1) AR018489A1 (de)
AT (1) ATE271607T1 (de)
AU (1) AU733825B2 (de)
BR (1) BR9612821A (de)
CA (1) CA2272130C (de)
DE (1) DE69632967T2 (de)
DK (1) DK0941329T3 (de)
EA (1) EA003772B1 (de)
ES (1) ES2225901T3 (de)
IL (1) IL130168A (de)
NO (1) NO324378B1 (de)
PT (1) PT941329E (de)
UA (1) UA73270C2 (de)
WO (1) WO1998023748A1 (de)
ZA (1) ZA9710737B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0941329B1 (de) * 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)
US20060240024A1 (en) 2003-02-28 2006-10-26 The Johns Hopkins University T cell regulation
KR20050082389A (ko) * 2004-02-18 2005-08-23 메덱스젠 주식회사 직렬 연쇄체를 갖는 면역접합체를 포함하는 장기이식합병증 치료용 약제학적 조성물
EP2044949A1 (de) * 2007-10-05 2009-04-08 Immutep Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
DK3356411T3 (da) 2015-10-02 2021-09-06 Hoffmann La Roche Bispecifikke antistoffer, der er specifikke for PD1 og TIM3
JP7000322B2 (ja) 2015-12-16 2022-02-04 メルク・シャープ・アンド・ドーム・コーポレーション 抗ｌａｇ３抗体および抗原結合性フラグメント
EP4201953A1 (de) 2017-04-03 2023-06-28 F. Hoffmann-La Roche AG Immunokonjugate eines anti-pd-1-antikörpers mit einem mutierten il-2 oder mit il-15
SG11201909154SA (en) 2017-04-05 2019-10-30 Hoffmann La Roche Bispecific antibodies specifically binding to pd1 and lag3
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656800B1 (fr) * 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5876708A (en) * 1992-02-19 1999-03-02 The General Hospital Corporation Allogeneic and xenogeneic transplantation
DK0758383T3 (da) 1994-05-06 2007-05-29 Roussy Inst Gustave Oplöselige polypeptidfraktioner af LAG-3-proteinet; fremgangsmåde til fremstilling; terapeutisk sammensætning; antiidiotypisk antistof
EP0941329B1 (de) * 1996-11-29 2004-07-21 Applied Research Systems ARS Holding N.V. Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)

Also Published As

Publication number Publication date
WO1998023748A1 (en) 1998-06-04
NO992569D0 (no) 1999-05-27
IL130168A0 (en) 2000-06-01
JP2001505770A (ja) 2001-05-08
JP3920928B2 (ja) 2007-05-30
EP0941329A1 (de) 1999-09-15
US6500422B2 (en) 2002-12-31
AR018489A1 (es) 2001-11-28
EA199900507A1 (ru) 2000-02-28
CA2272130C (en) 2007-10-23
AU733825B2 (en) 2001-05-24
DK0941329T3 (da) 2004-11-29
AU1066797A (en) 1998-06-22
KR20000053291A (ko) 2000-08-25
ZA9710737B (en) 1998-07-30
IL130168A (en) 2006-09-05
KR100481230B1 (ko) 2005-04-07
US20020081282A1 (en) 2002-06-27
EP0941329B1 (de) 2004-07-21
HK1023599A1 (en) 2000-09-15
CA2272130A1 (en) 1998-06-04
BR9612821A (pt) 2000-04-11
DE69632967T2 (de) 2005-08-11
PT941329E (pt) 2004-11-30
EA003772B1 (ru) 2003-08-28
NO992569L (no) 1999-05-27
DE69632967D1 (de) 2004-08-26
ES2225901T3 (es) 2005-03-16
NO324378B1 (no) 2007-10-01
UA73270C2 (en) 2005-07-15

Similar Documents

Publication Publication Date Title
DE69632967D1 (de) Vorbeugen des graftsabstosses in transplantaten und zur herstellung von universalen gentherapie wirtszell, unter anwendung von lymphozytenaktivierungsgen-3 (lag-3)
PL330313A1 (en) Tissue regeneration modulators
DE69634344D1 (de) Vorrichtung zur herstellung von emulsionen
DE60009955D1 (de) Methode und vorrichtung zur dynamischen gruppierung von kommunikationseinheiten in einem kommunikationssystem
WO2000052155A3 (en) Recombination of insertion modified nucleic acids
HUP9801216A3 (en) Dna molecules, preparation thereof and use thereof in gene therapy
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
DE69307733D1 (de) Calix-[4]-arene-bis-kronen, ihre herstellung und ihre anwendung zur selektiven extrahierung von cäsium und aktiniden
DE69511248D1 (de) Polycarbomate, verfahren zur herstellung von polycarbomaten und verfahren zur herstellung von polyisocyanaten
AU7704498A (en) Human frp and fragments thereof including methods for using them
ATE219767T1 (de) Verfahren zur herstellung von 2,4-dihydroxy- pyridin und 2,4-dihydroxy-3-nitropyridin
DE3576361D1 (de) Rekombinante dna, damit transformierter mikroorganismus, und verfahren zur herstellung von menschlicher cu-zn superoxiddismutase unter verwendung des transformierten mikroorganismus.
AU6028898A (en) Methods for cultivating cells and propagating viruses
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
DE69828191D1 (de) Verfahren zur herstellung von 2,6-dialkylnaphthalin
DE69013458D1 (de) Plasmide und Wirtszellen zur Expression von INA Protein (Ice nucleating protein).
DE69520072D1 (de) Verfahren zur entfernung von fortbildenden stoffen aus 1,4-butandiol und dessen verwendung zur herstellung von ptmeg
IS4899A (is) Lesitín-grunnuð örfleyti, sem innihalda prótínkljúfandi ensím, og aðferð til varanlegrar háreyðingar með ensími
WO1994016085A3 (en) Hybrid proteins having cross-linking and tissue-binding activities
DE69627655D1 (de) Schneidelement, stopfen und verfahren zur verhinderung des eindringens von spül-schlamm in das schneidelement
DE69729687D1 (de) Vorrichtung zur Rückgewinnung von Narkosemittel
DE59811544D1 (de) Verfahren zur herstellung von schutzkolloidfreien dispersionen und dispersionspulvern
DE69823191D1 (de) 1,2,3-thiadiazol-derivate, mittel zur kontrolle von pflanzenkrankheiten und methode zu seiner anwendung
AU3539095A (en) Hair transplantation apparatus and methods
NO20000961D0 (no) Nye vevs-spesifikke calpainer, samt fremgangsmåte for fremstilling og anvendelse derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0941329

Country of ref document: EP

REN Ceased due to non-payment of the annual fee